Blood product exports and vaccine sales power the strongest operating performance in years, but a ₩14 billion adverse tax swing and the deconsolidation of GC Wellbeing cut controlling shareholders' net income nearly a third.
Source: Q1 2026 Quarterly Report (58th Fiscal Year, January–March 2026) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
GC Corp posted its strongest quarterly operating result in recent memory in Q1 2026, with revenue climbing 13.5% year-on-year to ₩435.5 billion and operating profit surging 47.3% to ₩11.7 billion — a degree of operating leverage of roughly 3.5x signalling the company has crossed the threshold where its fixed cost base is genuinely being absorbed by incremental volume. Yet the headline net income figures tell a more complicated story: controlling shareholders' net income fell 31.0%, from ₩29.7 billion to ₩20.5 billion, and EPS retreated from ₩2,602 to ₩1,794. The divergence is not a sign of deteriorating operations. Pre-tax income actually expanded 71%, from ₩16.7 billion to ₩28.6 billion. The damage appeared further down the income statement — last year's ₩5.6 billion deferred tax benefit flipped to an ₩8.5 billion expense this quarter, generating a roughly ₩14.0 billion adverse swing in a single line. Layered on top was the disappearance of a base-period effect in which GC Wellbeing's subsidiary losses had been largely absorbed by minority shareholders in Q1 2025, artificially inflating the controlling shareholders' share that quarter. The clean read of Q1 2026 is the operating profit line — and it is up 47%.
A note on rounding: company IR materials and most financial press cite year-on-year operating profit growth at +46.3%, reflecting internally rounded figures. This report recalculates directly from DART-filed audited source data and arrives at +47.3%.
Balance Sheet
A Single Deconsolidation Simultaneously Shrinks Assets and Equity
| Item | Dec 31, 2025 (₩B) | Mar 31, 2026 (₩B) | Change |
|---|---|---|---|
| Cash and cash equivalents | 49.4 | 40.7 | -17.5% |
| Trade receivables | 402.7 | 371.1 | -7.8% |
| Inventories | 891.6 | 857.5 | -3.8% |
| Investments in associates/JVs | 121.6 | 85.8 | -29.5% |
| Property, plant & equipment | 845.0 | 779.3 | -7.8% |
| Intangible assets | 337.3 | 330.9 | -1.9% |
| Total assets | 2,971.1 | 2,775.9 | -6.6% |
Total assets contracted by ₩195.3 billion over the three-month period, driven almost entirely by a single accounting event. The number of consolidated subsidiaries fell from 21 to 19, with the deconsolidation of GC Wellbeing as the pivotal change — the notes describe financial information recognised only "until loss of control." GC Wellbeing's exit pulled PP&E down by ₩65.6 billion and brought intangibles and other operating assets with it. The investment-in-associates line fell from ₩121.6 billion to ₩85.8 billion as the former subsidiary was reclassified out of the consolidation perimeter entirely.
Inventories remained large at ₩857.5 billion — 30.9% of total assets — a structural feature of the blood products business, which requires substantial plasma raw material stockpiles and finished vaccine product buffers. A 3.8% quarter-on-quarter reduction is encouraging but does not materially alter the working capital intensity of the model.
Equity: Controlling Stake Grows, Non-Controlling Interests Collapse
Retained earnings edged up from ₩796.5 billion to ₩799.9 billion, absorbing the quarter's ₩3.4 billion net addition. Other comprehensive income improved from ₩2.0 billion to ₩9.9 billion, with ₩6.9 billion in foreign currency translation gains reflecting the stronger dollar-denominated contribution from the U.S. entity marketing ALYGLO and other overseas subsidiaries. Controlling shareholders' equity rose 0.9%, from ₩1,217.5 billion to ₩1,228.7 billion.
The most dramatic balance sheet move was in non-controlling interests, which collapsed 54.6% from ₩176.8 billion to ₩80.3 billion. GC Wellbeing's minority shareholder stake exited the consolidation perimeter in its entirety. This single reclassification accounts for the majority of the ₩85.3 billion decline in total equity; the controlling shareholders' stake expanded, not contracted.
Debt Structure: High Short-Term Concentration
Total liabilities fell from ₩1,576.8 billion to ₩1,466.9 billion, but the composition of financial debt warrants close attention. Short-term borrowings stand at ₩201.4 billion, the current portion of long-term debt at ₩344.3 billion, and non-current long-term borrowings at ₩260.7 billion — total interest-bearing debt of approximately ₩806.4 billion. Netting out ₩40.7 billion in cash, net debt is roughly ₩765.7 billion, approximately 58.5% of total equity. More pressingly, the ₩545.7 billion (68% of total borrowings) falling due within twelve months creates a recurring rollover requirement. This quarter alone saw ₩475.0 billion in new short-term borrowings drawn down against ₩593.8 billion repaid — a high-volume cycling that will recur each quarter. The debt-to-equity ratio improved marginally from 113.1% to 112.1%. IFRS 16 right-of-use assets of ₩103.6 billion are matched by lease liabilities of ₩13.2 billion (current) and ₩94.8 billion (non-current).
Income Statement
Core Operations Accelerating; Net Income Line Distorted by Structural Shifts
| Metric | FY2024 | FY2025 | Q1 2025 | Q1 2026 |
|---|---|---|---|---|
| Revenue (₩B) | 1,679.9 | 1,991.3 | 383.8 | 435.5 |
| Operating profit (₩B) | 32.1 | 69.2 | 8.0 | 11.7 |
| Operating margin (%) | 1.9 | 3.5 | 2.1 | 2.7 |
| Net income — consolidated (₩B) | -42.6 | -29.7 | 22.3 | 20.1 |
| Net income — controlling shareholders (₩B) | -26.3 | -4.7 | 29.7 | 20.5 |
Annual revenue grew 18.5% from FY2024 to FY2025, and that trajectory carried through Q1 2026 at a 13.5% year-on-year pace. The signal embedded in those rates matters more than the rates themselves: a 13.5% revenue gain produced a 47.3% operating profit gain, implying roughly 3.5x operating leverage. For the annual series, operating profit more than doubled from ₩32.1 billion in FY2024 to ₩69.2 billion in FY2025. The driver is structural: GC Corp's Ochang manufacturing facility and U.S. sales of ALYGLO — its 10% intravenous immunoglobulin launched in the United States in August 2024, following FDA approval in December 2023 — have reached a scale where incremental revenue flows disproportionately to the operating line. Two consecutive years of annual net losses ended at the quarterly level, with GC turning operating and pre-tax profitable on a recurring basis.
Cost Structure: Gross Margin Slips, SG&A Leverage Compensates
Gross margin tightened from 29.4% in Q1 2025 to 28.2% in Q1 2026, with the cost-of-revenue ratio rising from 70.6% to 71.8%. Higher plasma procurement costs and an evolving product mix applied upward pressure on the gross line. The operating margin improvement from 2.1% to 2.7% came entirely from SG&A leverage: selling, general and administrative costs grew 6.0% — from ₩104.8 billion to ₩111.0 billion — well below the 13.5% revenue expansion. As long as the plasma cost environment does not deteriorate further, additional revenue growth should continue to fall through to operating profit more than proportionally.
Stripping Out the One-Time Items: A Tale of Two Quarters
Both the current and the year-ago quarter were heavily shaped by non-recurring lines, but in opposite directions, making a simple year-on-year net income comparison misleading.
In Q1 2026, other income spiked to ₩39.4 billion — more than ten times the ₩3.7 billion recorded in Q1 2025 — driven by the gain on deconsolidating GC Wellbeing. In Q1 2025, equity income from associates contributed ₩31.1 billion (reflecting remeasurement gains on associate stakes); this quarter that line turned to a ₩2.1 billion loss as the underlying position normalised. The net of those two swings is roughly offsetting — explaining why, despite the noise, pre-tax income rose 71% rather than falling.
The actual damage to post-tax income came from the tax line. A ₩5.6 billion deferred tax benefit in Q1 2025 became an ₩8.5 billion tax expense in Q1 2026 — an adverse year-on-year swing of approximately ₩14.1 billion within a single line. The base-period effect from minority shareholders absorbing a disproportionate share of GC Wellbeing's 2025 losses — which had inflated the controlling shareholders' residual — also unwound. Finance costs declined modestly, from ₩26.9 billion to ₩22.5 billion, offering partial relief.
The operating profit line, at +47.3%, is the most reliable measure of underlying performance improvement this quarter. Everything else in the income statement is best understood as noise generated by structural accounting events and a tax timing reversal.
Cash Flow
Seasonal Working Capital Drain Narrows Sharply; Subsidiary Sale Converts Investing CF to Positive
| Item | Q1 2025 (₩B) | Q1 2026 (₩B) | Change |
|---|---|---|---|
| Operating cash flow | -86.2 | -24.5 | +61.7 |
| Investing cash flow | -47.4 | +5.8 | +53.2 |
| Financing cash flow | +201.1 | +4.2 | -196.9 |
| Closing cash | ~89.6* | 40.7 | — |
Q1 2025 closing balance per that period's statement
Operating cash flow improved substantially from -₩86.2 billion to -₩24.5 billion, though it remained negative. GC Corp's revenue is inherently seasonal: influenza vaccine sales concentrate in the second half, generating predictable first-half working capital outflows. Reducing that outflow to less than one-third of the prior year's level is a genuine positive, indicating faster collection cycles or tighter inventory management. Cash earnings quality (operating CF divided by net income) remains negative, but this reflects seasonal timing rather than deteriorating earnings.
Wellbeing Proceeds Redirect to Capex, Not Debt
Investing cash flow swung from -₩47.4 billion to +₩5.8 billion. The decisive contributor was ₩48.0 billion in proceeds from the disposal of GC Wellbeing. The transaction counterparty was GC Holdings — GC Corp's controlling parent — a related-party transaction rather than an arm's-length market sale, which modestly qualifies the gain's economic signalling value. The proceeds were not directed toward debt reduction. Capital expenditure more than tripled, from ₩10.0 billion to ₩33.0 billion (7.6% of revenue), and intangible asset acquisitions consumed a further ₩4.9 billion. The capital allocation logic is clear: proceeds from the non-core subsidiary are being redeployed into blood products manufacturing capacity expansion, prioritising volume growth over balance sheet repair.
Free cash flow (operating cash flow minus capex) was -₩57.5 billion, a seasonal negative. Financing activities generated a net ₩4.2 billion after the ₩475.0 billion in new short-term borrowings and ₩593.8 billion in repayments that characterise the high-volume rollover dynamic. The dividend payment was negligible at ₩0.027 billion. Closing cash declined from ₩49.4 billion at year-end to ₩40.7 billion.
Key Findings
ALYGLO and the U.S. Blood Products Market
Blood products contributed approximately ₩178.4 billion in segment revenue before intercompany eliminations — roughly 41% of the consolidated total — with export sales at ₩88.5 billion nearly matching domestic sales of ₩89.9 billion. ALYGLO, a 10% intravenous immunoglobulin indicated for primary immunodeficiency diseases, entered the world's largest immune globulin market in August 2024. GC Corp has secured FDA approval for seven U.S. domestic plasma collection centres and is expanding that network. The pace of U.S. plasma self-sufficiency growth and the trajectory of American ALYGLO volumes will be the primary determinants of GC Corp's margin direction over the next several years. The U.S. IVIG market is intensely competitive — Takeda's Gammagard, Grifols' Gamunex-C, and CSL Behring's Privigen are established incumbents — and GC's ability to maintain pricing while scaling supply is not guaranteed.
Segment Revenue Concentration
The full Q1 2026 segment breakdown before intercompany eliminations:
| Segment | Q1 2026 (₩B) |
|---|---|
| Blood products | 178.4 |
| General pharmaceuticals | 81.6 |
| Other pharmaceuticals | 80.8 |
| Vaccines | 56.9 |
| Diagnostic/analytical | 37.8 |
| OTC | 27.8 |
| Other | 6.3 |
| Segment total (pre-elimination) | 469.5 |
| Intercompany eliminations | (33.9) |
| Consolidated revenue | 435.5 |
Blood products alone exceed 40% of consolidated revenue. ALYGLO's pricing environment and competitive dynamics in the U.S. market therefore transmit directly into group-level results with limited diversification buffer.
R&D Investment Maintained Through Two Loss Years
Research and development expenditure as a percentage of revenue tracked at 10.4% in FY2024, 8.6% in FY2025, and approximately 9.5% in Q1 2026 — consistent investment sustained through two consecutive years of annual net losses. The pipeline includes Hunterase (a treatment for Hunter syndrome; GC Corp holds what it describes as the world's first commercially available intracerebroventricular-route formulation, marketed in more than ten countries), GreenGene F (a recombinant Factor VIII for haemophilia, approved by China's NMPA), and a next-generation shingles vaccine under development at U.S. subsidiary Curevo Inc. (Phase 2 expansion stage). Maintaining double-digit R&D expenditure through a loss cycle signals pipeline conviction, but compresses the margin available for profitability normalisation in the near term.
Debt Maturity Wall and Finance Cost Overhang
Of ₩806.4 billion in total interest-bearing debt, 68% — or ₩545.7 billion — matures within twelve months, requiring continuous refinancing. Finance costs for the quarter were ₩22.5 billion, equal to 1.9 times operating profit of ₩11.7 billion. Debt service alone is capable of eliminating a full quarter's operating earnings. The decision to direct GC Wellbeing disposal proceeds toward capex rather than debt reduction prioritises growth over balance sheet repair. In a rate-stable or rate-declining environment, this is supportable if ALYGLO revenues ramp as anticipated. In a scenario of refinancing friction or rate elevation, the short-duration maturity profile is a structural vulnerability.
Outlook
The operating profit trajectory — ₩32.1 billion in FY2024, ₩69.2 billion in FY2025, ₩11.7 billion in a single quarter of FY2026 — describes a business that has relearned how to convert revenue growth into operating earnings. The seasonal H2 vaccine contribution has not yet arrived; if the operating leverage demonstrated in Q1 sustains through Q2 and the second half, FY2026 operating profit could comfortably surpass FY2025's ₩69.2 billion.
The bear case rests on three structural tensions. Gross margin is already under pressure from plasma procurement costs and product mix, with the cost-of-revenue ratio at 71.8% and trending upward. If that continues, SG&A leverage alone cannot drive sustained margin expansion. Finance costs at 1.9x quarterly operating profit mean the gap between an operating recovery and a meaningful bottom-line recovery remains wide, and a refinancing cycle that hardens rates would narrow it further. And the Q1 2026 bottom-line figures were partially supported by the GC Wellbeing disposal gain — a related-party transaction at non-arm's-length pricing — making the quarter's net income quality imperfect as a baseline.
The path forward is structurally legible. ALYGLO's continued penetration of the U.S. IVIG market, the expansion of U.S. plasma collection capacity, the seasonal H2 vaccine contribution, and the resolution of the annual tax position in GC Corp's favour could together produce a sustained profitability inflection. But confirmation of that inflection — clean of one-time items in both directions — requires at minimum two to three more quarters of data before the pattern can be treated as durable.
This report is prepared for informational purposes based on GC Corp's Q1 2026 Quarterly Report (58th Fiscal Year) as filed with DART on May 15, 2026, and does not constitute investment advice or a solicitation to buy or sell any security. GC Corp (006280.KS) is a publicly listed company on the Korea Stock Exchange. All figures are on a consolidated basis unless otherwise noted; calculated ratios are presented alongside source figures for verification. The author is not a registered investment adviser and holds no position in any securities mentioned. Publication date: July 20, 2026.
Sources: DART Q1 2026 Quarterly Report (GC Corp) · GC Corp IR (KOSPI 006280.KS)
